Iloprost Inhalation for the Treatment of Severe Persistent Pulmonary Hypertension of the Newborn, Experience at QSNICH
Uraiwan Chotigeat MD*, Maneewan Champrasert MD**, Meera Khorana MD*, Varaporn Sangtaweesin MD*, Wiboon Kanjanapattanakul MD*
Affiliation : * Neonatal Unit, Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand ** Department of Pediatrics, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand
Background : Persistent pulmonary hypertension of the newborn (PPHN) is the most serious condition that causes high
mortality in term and post term infants. The authors have an experience of using high frequency oscillatory ventilation
(HFOV) and inhaled nitric oxide (iNO) for treatment of this condition with a good result. However, due to high cost of iNo,
other pulmonary vasodilators have been use. Sildenafil had some side effects of systemic hypotension. Thus, inhaled iloprost
was introduced for treatment of PPHN at our institute.
Objective : To evaluate the outcome of inhaled iloprost for the treatment of PPHN.
Material and Method: This was a retrospective study. The data from medical records of newborns, diagnosed as persistent
pulmonary hypertension of the newborn and had received inhaled iloprost from October 1st, 2008-October 31 st, 2012, were
reviewed.
Results : Nineteen cases of PPHN treated with inhaled iloprost were reviewed. Male to female ratio was 1.37:1 (11:8). Mean
birth weight and gestational age of these patients were 2,997+531.63 grams and 37.9+2.51 weeks, respectively. Meconium
aspiration syndrome was the leading underlying cause of this condition. The mortality rate in this study was 21% (4 from 19
cases). After the addition of inhaled iloprost, the oxygen index (OI) in the survivor group decreased significantly at one hour
after treatment (from 32.89 to 22.06, 18.76, 13.76 at 1, 6, 12 hours, respectively). Oxygen saturation (SpO2) continued
increasing after treatment in the survivor group (from 82.40% to 92.20%, 95.00%, 95.80% at 1, 6, 12 hours, respectively)
with significant difference at one hour. There was a significant difference of OI and SpO2 between the survivor and non-
survivor groups after treatment. Low Apgar score at 5 minutes and early diagnosis of PPHN were found statistically
significant different in the non- survivor compared to the survivor groups.
Conclusion : Inhaled iloprost could be used as an alternative treatment of PPHN without side effects of systemic hypotension.
Keywords : Inhaled iloprost, PPHN
